Figure 1.
Clinical outcomes of the two groups (p value = 4×10−13 – as calculated by Fisher’s exact test)
| Clinical outcome | Study group (42 patients) | Control group (42 patients) |
|---|---|---|
| Improved | 12 | 42 |
| Worsened | 14 | 0 |
| Deceased | 16 | 0 |
Baseline laboratory parameters for the two groups;
| Laboratory parameter | Study group Median value, (Q1-Q3) | Control group Median value, (Q1-Q3) | p-value |
|---|---|---|---|
| Serum creatinine level (mg/dL) | 0.885 (0.71–1.165) | 0.925 (0.7625–1.11) | 0.71 |
| Hemoglobin level (g/dL) | 12.5 (10.03–13.55) | 14 (12.3–14.875) | 0.0064 |
| Neutrophil count (*1000/uL) | 9 (7–12.3) | 6.78 (4.95–8.61) | 0.00095 |
| White blood cells count (*1000/uL) | 11 (8.95–15) | 9.26 (7.55–12.1775) | 0.028 |
| Platelet count (*1000/uL) | 217 (153.65–260.75) | 249.5 (195.25–291) | 0.026 |
| Erythrocyte sedimentation rate (mm/h) | 37.5 (19.25–75.75) | 20 (9.75–37.75) | 0.009 |
Baseline characteristics of the two groups analyzed with Fisher’s exact test_
| Characteristic | Odds ratio (95% confidence interval) | (a,b,c,d) |
|---|---|---|
| Male gender | 0.91 (0.35–2.33) | (20, 22, 21, 21) |
| Arterial hypertension | 0.91 (0.35–2.33) | (20, 22, 21, 21) |
| Type 2 diabetes | 1 (0.34–2.97) | (31, 11, 31, 11) |
| Dyslipidemia | 0.41 (0.15–1.08) | (20, 22, 29, 13) |
| Chronic kidney disease | 1.57 (0.34–8.24) | (38, 4, 36, 6) |
| Chronic heart failure | 2.11 (0.7–6.7) | (34, 8, 28, 14) |
| History of myocardial infarction | 0.3 (0.03–1.84) | (36, 6, 40, 2) |
| Concomitant neoplasm | 2.09 (0.28–24.34) | (40, 2, 38, 4) |
The diagnostic performance of imaging findings on brain CT
| Brain CT characteristic | Sn | Sp | LR+ | LR− |
|---|---|---|---|---|
| Hemorrhagic transformation | 0.19 | 0.905 | 2 | 0.895 |
| Multiple lesions | 0.786 | 0.857 | 5.497 | 0.25 |
| Multiple arterial territories | 0.738 | 0.929 | 10.394 | 0.282 |
| Watershed lesions | 0.429 | 0.857 | 3 | 0.666 |